SCHEMBL25950824

SCHEMBL25950824

CC(C)(C)c1cc(Cl)cnc1CO

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.34
MAPK1 P28482 3/20 0.34
HTT P42858 1/20 0.34
KDM4E B2RXH2 4/20 0.33
GAA P10253 1/20 0.33
CCR9 P51686 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
ALDH1A1 P00352 4/20 0.32
DHFR P00374 2/20 0.32
PLAU P00749 2/20 0.32
TP53 P04637 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
HIF1A Q16665 2/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP1A2 P05177 2/20 0.31
ALOX15 P16050 2/20 0.31
MAPT P10636 1/20 0.31
ATP2A2 P16615 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12401830 0.83 CRHR1 (0.36) LMNAMAPK1HTTKDM4EGAA
SCHEMBL23478377 0.75 IDO1 (0.39) HTTDHFRPLAUCYP1A2GLA
SCHEMBL14586459 0.75 ALDH1A1 (0.39) LMNAMAPK1HTTKDM4EGAA
SCHEMBL10264977 0.74 HTT (0.33) LMNAMAPK1HTTKDM4EGAA
SCHEMBL990259 0.74 PLAU (0.47) LMNAMAPK1HTTKDM4EGAA
SCHEMBL13145646 0.72 L3MBTL1 (0.33) LMNAMAPK1HTTKDM4ESMN1; SMN2
SCHEMBL18911298 0.72 ALDH1A1 (0.42) LMNAMAPK1HTTKDM4EALDH1A1
SCHEMBL22949453 0.72 L3MBTL1 (0.33) LMNAMAPK1HTTKDM4ESMN1; SMN2
SCHEMBL12401753 0.72 LMNA (0.43) LMNAMAPK1HTTKDM4EGAA
SCHEMBL6370666 0.71 L3MBTL1 (0.35) LMNAMAPK1HTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B LMNA 2905/4885MAPK1 2324/4885HTT 1027/4885
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B LMNA 2905/4885MAPK1 2324/4885HTT 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.